New Double-Antibody attack aims to wipe out breast cancer before surgery
NCT ID NCT07294534
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a new drug combination (HLX87 plus HLX22 or pertuzumab) works better than standard chemotherapy before surgery for people with HER2-positive early or locally advanced breast cancer. About 817 participants will be randomly assigned to one of three treatment groups. The main goal is to see if the cancer completely disappears in the breast and lymph nodes at the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HLX87 (a targeted drug that delivers chemotherapy directly to HER2-positive cancer cells) combined with HLX22 (another anti-HER2 antibody) or pertuzumab
What this could lead to
If successful, this could offer a more effective pre-surgery treatment for HER2-positive breast cancer, potentially increasing the chance of eliminating all cancer before surgery.
What could go wrong
This is an early-to-mid stage trial (Phase 2/3) and the new drug combination may not work better than current standard therapy. Side effects from the targeted chemotherapy could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 + BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••